Yoko Ogawara

862 citations
14 papers · 591 indexed · h-index 6
Topics
Acute Myeloid Leukemia Research (7 papers)Histone Deacetylase Inhibitors Research (5 papers)Cancer, Hypoxia, and Metabolism (4 papers)

In The Last Decade

Yoko Ogawara

12 papers receiving 580 citations

Peers

Yoko Ogawara
Comparison fields: 5 of 81
  • Molecular Biology 445
  • Oncology 213
  • Cancer Research 118
  • Hematology 56
  • Pathology and Forensic Medicine 52
Replace Anchit Khanna with:
Anchit Khanna Australia
Joji Nakayama Japan
Margaret H.L. Ng Hong Kong
Lu Yue China
Kristin M. Stadelman United States
Sonia Mohinta United States
Jun-Ying Zhou United States
Gloria Manzotti Italy
JI Epstein United States
Yoko Ogawara relative to Anchit Khanna Australia Anchit Khanna's profile →
Citations per field
00.5×1.5×
Anchit Khanna · 1×
Citations per year

Countries citing papers authored by Yoko Ogawara

Since Specialization
Citations

This map shows the geographic impact of Yoko Ogawara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoko Ogawara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoko Ogawara more than expected).

Fields of papers citing papers by Yoko Ogawara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoko Ogawara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoko Ogawara. The network helps show where Yoko Ogawara may publish in the future.

Co-authorship network of co-authors of Yoko Ogawara

This figure shows the co-authorship network connecting the top 25 collaborators of Yoko Ogawara. A scholar is included among the top collaborators of Yoko Ogawara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoko Ogawara. Yoko Ogawara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
#WorkIndexed citations
1 7
2 2
3 20
4
The mutant IDH1 inhibitor prevents growth of glioblastoma with IDH1 mutation in patient-derived xenograft (PDX) model
0
5 2
6 45
7 1
8 0
9 2
10 1
11 9
12 1
13 488
14 13

About Yoko Ogawara

Yoko Ogawara is a scholar working on Hematology, Genetics and Cancer Research, having authored 14 papers that have together received 591 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (7 papers), Histone Deacetylase Inhibitors Research (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). The work is most often cited by research in Cancer Research (118 citations), Oncology (213 citations) and Molecular Biology (445 citations). Yoko Ogawara has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Toshiyuki Obata, Shohei Kishishita, Norihisa Masuyama, Yukiko Gotoh, Keiji Tanaka, Toshiaki Suzuki, Issay Kitabayashi, Takuo Katsumoto, Yuki Kagiyama and Yukiko Aikawa. Their work appears in journals such as Journal of Biological Chemistry, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026